Detalles de la búsqueda
1.
Impact of systemic therapies in metastatic melanoma of unknown primary: A study from MELBASE, a French multicentric prospective cohort.
J Am Acad Dermatol
; 88(4): 808-815, 2023 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-36543626
2.
Risk of irAEs in patients with autoimmune diseases treated by immune checkpoint inhibitors for stage III or IV melanoma: results from a matched case-control study.
Ann Rheum Dis
; 81(10): 1445-1452, 2022 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-35788496
3.
Late-onset adverse events of anti-PD1 therapy in melanoma patients: An observational study from MELBASE, a nationwide prospective cohort.
J Am Acad Dermatol
; 86(2): 345-352, 2022 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-34153388
4.
Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study.
Lancet Oncol
; 22(6): 836-847, 2021 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-33989557
5.
Melanoma recurrence patterns and management after adjuvant targeted therapy: a multicentre analysis.
Br J Cancer
; 124(3): 574-580, 2021 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-33087895
6.
Quality-of-life assessment in French patients with metastatic melanoma in real life.
Cancer
; 126(3): 611-618, 2020 02 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31639198
7.
Ipilimumab versus ipilimumab plus anti-PD-1 for metastatic melanoma - Authors' reply.
Lancet Oncol
; 22(8): e343-e344, 2021 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-34339647
8.
Combined PDE4+MEK inhibition shows antiproliferative effects in NRASQ61 mutated melanoma preclinical models.
Melanoma Res
; 34(2): 186-192, 2024 04 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-38141200
9.
PROM2 overexpression induces metastatic potential through epithelial-to-mesenchymal transition and ferroptosis resistance in human cancers.
Clin Transl Med
; 14(3): e1632, 2024 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-38515278
10.
Efficacy and safety of 'Second Adjuvant' therapy with BRAF/MEK inhibitors after local therapy for recurrent melanoma following adjuvant PD-1 based immunotherapy.
Eur J Cancer
; 199: 113561, 2024 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-38278009
11.
The features and management of acquired resistance to PD1-based therapy in metastatic melanoma.
Eur J Cancer
; 196: 113441, 2024 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-37988842
12.
Efficacy of ipilimumab 3 mg/kg following progression on low-dose ipilimumab in metastatic melanoma.
Eur J Cancer
; 186: 12-21, 2023 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-37018924
13.
Differential gradients of immunotherapy vs targeted therapy efficacy according to the sun-exposure pattern of the site of occurrence of primary melanoma: a multicenter prospective cohort study (MelBase).
Front Oncol
; 13: 1250026, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37936607
14.
18FDG PET Assessment of Therapeutic Response in Patients with Advanced or Metastatic Melanoma Treated with First-Line Immune Checkpoint Inhibitors.
Cancers (Basel)
; 14(13)2022 Jun 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-35804963
15.
Efficacy and safety of anti-PD1 monotherapy or in combination with ipilimumab after BRAF/MEK inhibitors in patients with BRAF mutant metastatic melanoma.
J Immunother Cancer
; 10(7)2022 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-35798536
16.
Cost-Effectiveness Analysis of Sequential Treatment Strategies for Advanced Melanoma in Real Life in France.
Curr Oncol
; 29(12): 9255-9270, 2022 11 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-36547139
17.
Efficacy of anti-PD-1 and ipilimumab alone or in combination in acral melanoma.
J Immunother Cancer
; 10(7)2022 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-35793872
18.
Real-world effectiveness of pembrolizumab in advanced melanoma: analysis of a French national clinicobiological database.
Immunotherapy
; 13(11): 905-916, 2021 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-34074114
19.
Combination anti-PD1 and ipilimumab therapy in patients with advanced melanoma and pre-existing autoimmune disorders.
J Immunother Cancer
; 9(5)2021 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-33963010
20.
Severe immune-related hepatitis induced by immune checkpoint inhibitors: Clinical features and management proposal.
Clin Res Hepatol Gastroenterol
; 45(2): 101491, 2021 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-32773362